Scientific resources for painful diabetic peripheral neuropathy of the feet
You are accessing an educational resource page for US healthcare professionals only. Explore scientific resources designed to support the identification, clinical understanding, and management of painful diabetic peripheral neuropathy (PDPN) of the feet.
Educational library
Capsaicin 8% topical system for PDPN of the feet
This resource has been developed by Averitas Pharma as an educational resource for US healthcare professionals (HCPs). The content provides general scientific information and clinical data on capsaicin 8% topical system related to the painful diabetic peripheral neuropathy (PDPN) of the feet indication.
The information presented is intended to support scientific and educational discussion and should be interpreted in the context of the full Prescribing Information. This content does not endorse any indications, dosages, or claims beyond those described in the Prescribing Information.
This educational library includes content relating to capsaicin 8% topical system, including:
The PDPN treatment landscape
Mechanism of action
Clinical trial and real-world data on efficacy and safety
Educational resource for HCPs: Capsaicin 8 % topical system for PDPN of the feet.
Download the library containing educational information on the capsaicin 8% topical system,
including the mechanism of action, clinical and real-world data, and the PDPN treatment landscape
Download Confirmed
The requested resource has been downloaded.
Contact the medical team for further information or questions
You are now leaving
the Averitas Medical Affairs Website
For US healthcare professionals only
The purpose of this Averitas Pharma website is to provide educational information to US healthcare professionals only.
The content is not intended as promotion of medical products or as medical advice. Decisions regarding patient care are
the responsibility of healthcare professionals, guided by their expertise, licensure, and understanding of each
patient's unique needs. The content presented may include information pertaining to products or uses that have not
received approval form the US Food and Drug administration. Averitas Pharma does not recommend the use of its products
outside the approved prescribing information. For full prescribing information, including indications,
contraindications, warnings, precautions, and adverse events, please refer to the approved product labeling. All images
on this site are for illustrative purposes only and may include actors.